Sex-Selective Discrimination Common in Indian Wombs: US Study
By Hindustan Times,
Hindustan Times
| 03. 31. 2013
Indian women carrying male foetuses are likelier to receive pre-natal medical care than their counterparts pregnant with girls, a new research by American scientists suggests, raising fresh, uncomfortable questions about the discrimination against girls that starts in the womb.
The scientists, who studied 30,000 Indian women captured in the National Family Health Survey, found that those pregnant with boys were more likely to go to pre-natal medical appointments, take iron supplements, deliver babies in healthcare facilities and receive tetanus shots.
“It paints a pretty dire picture of what’s happening,” said Leah Lakdawala, an assistant professor of economics at Michigan State University.
The research by Lakdawala and Prashant Bhardwaj of the University of California San Diego is published in the latest issue of the reputed Journal of Human Resources.
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...